How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Torregrosa-Quesada ME
- García-Martínez A
- Silva-Ortega S
- Martínez-López S
- Fajardo C
- Lamas C
- Aranda I
- Picó A
Grupos
Abstract
The classification of pituitary neuroendocrine tumors (PitNETs) subtypes continues generating interest. In 2017, the World Health Organization (WHO) proposed considering the immunohistochemical (IHC) analysis of pituitary-specific transcription factors (TF) for their typification. The present study targeted the quantification of pituitary-specific TF ( TPIT , PIT-1 , SF-1 , GATA2 , ESR1 ) gene expression by RT-qPCR to overcome the shortcomings of IHC and to complement it. We analyzed 251 tumors from our collection of PitNETs and performed additional IHC studies in a subset of 56 samples to analyze the concordance between gene and protein expression of the TF. The molecular and IHC studies allowed us to significantly reduce the percentage of null cell tumors in our series, most of which were reclassified as gonadotroph tumors. The concordance between the molecular and the immunohistochemical studies was good for tumors coming from the corticotroph and Pit-1 lineages but worsened for the rest of the tumors. Indeed, the RT-qPCR helped to improve the typification of plurihormonal Pit-1 and unusual tumors. Overall, our results suggest that the RT-qPCR of pituitary-specific TF and hormone genes could help pathologists, endocrinologists, and neurosurgeons to improve the management of patients with pituitary tumors.
Datos de la publicación
- ISSN/ISSNe:
- 2072-6694, 2072-6694
- Tipo:
- Article
- Páginas:
- -
- Factor de Impacto:
- 1,938 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cancers MDPI
Citas Recibidas en Web of Science: 11
Documentos
- No hay documentos
Filiaciones
Keywords
- classification of pituitary tumors, pituitary neuroendocrine tumors, pituitary-specific hormone genes, pituitary-specific transcription factor genes, pituitary-specific transcription factor proteins
Proyectos asociados
ESTUDIO FASE III, MULTICENTRICO, ALEATORIZADO, DOBLE CIEGO DE 48 SEMANAS, CON UN PERIDO INICIAL DE 12 SEMANAS CONTROLADO CON PLACEBO, PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE OSILODROSTAT EN PACIENTES CON ENFERMEDADES DE CUSHING.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2302 . 2016
ESTUDIO DE EXTENSIÓN, MULTICÉNTRICO, ABIERTO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO EN PACIENTES CON SÍNDROME DE CUSHING ENDÓGENO QUE HAYAN COMPLETADO UN ESTUDIO ANTERIOR DE OSILODROSTAT (LCI699) PATROCINADO POR NOVARTIS Y QUE EL INVESTIGADOR CONSIDERE QUE SE ESTÁN BENEFICIANDO DEL TRATAMIENTO CONTINUADO CON OSILODROSTAT.
Investigador Principal: ROSA CÁMARA GÓMEZ
CLCI699C2X01B . 2018
ESTUDIO OBSERVACIONAL, TRASVERSAL Y MULTICÉNTRICO PARA VALORAR EL CUMPLIMENTO TERAPÉUTICO CON SOMAVERT® EN PACIENTES CON ACROMEGALIA EN CONDICIONES DE PRÁCTICA CLÍNICA HABITUAL.
Investigador Principal: ROSA CÁMARA GÓMEZ
PFI-PEG-2014-01 . 2015
ESTUDIO MUNDIAL SOBRE EL CONTROL Y LAS COMPLICACIONES DEL HIPOTITUITARISMO (HYPOCCS).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
B9R-MC-GDGA . 2011
Cita
Torregrosa ME,García A,Silva S,Martínez S,Cámara R,Fajardo C,Lamas C,Aranda I,Picó A. How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?. Cancers (Basel). 2019. 11. (12):1990. IF:6,126. (1).